Relmada Therapeutics stock surges 25% on bladder cancer data By Investing.com

Relmada reported a 12-month complete response (CR) rate of 76% (95% CR at any time) in its Phase 2 NDV-01 trial, with 80% 12-month CR (94% any time) in BCG-unresponsive patients and no progression to muscle-invasive disease; shares jumped ~25% on the news. Safety showed no Grade ≥3 treatment-related AEs and no treatment-related discontinuations, though 63% of treated patients experienced any treatment-related AE (most common dysuria 54%). Management plans a mid-2026 start to the Phase 3 RESCUE registrational program and announced a ~$160.0M PIPE, selling 29,474,569 shares at $4.75 and pre-funded warrants for 4,210,527 shares at $4.749, expected to close ~Mar 11, 2026.

Analysis

This print is a classic binary biotech rerating: an attractive safety/tolerability profile for an intravesical candidate changes the adoption vector from high-risk surgical pathways and systemic immunotherapy toward outpatient urology clinics. That migration would shift revenue pools (OR time, inpatient margins) into lower-cost clinic-administered procedures and favor partners with manufacturing scale for repeated-dose intravesical products; winning commercial models will emphasize ease-of-delivery and low monitoring burden.

Second-order winners include specialty CROs and fill/finish vendors that can support high-frequency per-patient dosing and urology-focused sales forces; hospitals and surgeons could see a modest decline in radical-cystectomy case volumes if uptake is meaningful, pressuring surgical service lines but improving capacity for other procedures. Payers will focus on durability vs cost-per-episode; a therapy that avoids systemic checkpoint use or surgery will gain leverage in contracting even if priced at a premium per episode.

Principal near-term risks are classic: Phase 3 readout risk, broader safety signals in larger populations, and the regulatory bar on durability beyond a single-year landmark. Market microstructure risks include financing-driven dilution and option/warrant overhang compressing the stock into the next 4–12 months; this can create outsized short-term volatility irrespective of clinical progress.

From a trading standpoint the optimal approach is asymmetric exposure: small, size-controlled long exposure to capture a successful registrational program while using defined-risk option structures or a sector hedge to limit downside from a negative Phase 3 or repricing around financing. Monitor early uptake signals from investigator-initiated use and payer commentary — those will move the mid-term commercial probability far more than a single interim readout.

Key Decisions for Investors

• Long RLMD equity (ticker: RLMD) — 1–2% portfolio position entered on a 10–25% pullback or incrementally now with stop at 40% downside. R/R: asymmetric — if Phase 3 initiation and commercial narrative hold, >2x upside in 6–18 months; downside capped by stop/hedge.
• Defined-risk options — buy a Jan‑2027 call spread on RLMD to capture the mid-2026 to 2027 registrational window while capping premium. Allocate <0.5% portfolio; max loss = premium, upside >2x if positive Phase 3 signals or commercial traction.
• Tactical short near-term volatility around financing — purchase a 6–12 week put spread (RLMD) sized to 0.25–0.5% portfolio to protect against dilution-driven repricing. Expect this to pay off if shares compress 20–50% into/after the financing close.
• Pair trade to hedge sector risk — long RLMD vs short equal-dollar biotech ETF (e.g., IBB or XBI) for 6–12 months. This isolates idiosyncratic clinical/commercial upside while neutralizing broad biotech beta; size 1% net long.
• Event watch & scale plan — if early Phase 3 enrollment metrics and payer pre-reimbursement signals are positive within 3–9 months, scale longs to 3–4% and roll options out; conversely, tighten hedges if emerging safety or payer pushback appears.